

Treatment of Alcohol and Opioid Use Disorders

Best Practices for outpatient and emergency settings

May 20, 2025

- ASAM Definition of Addiction. Asam.org. Accessed June 11, 2021.
<https://www.asam.org/Quality-Science/definition-of-addiction>
- Balldin, J., Berglund, M., Borg, S., Månsson, M., Bendtsen, P., Franck, J., Gustafsson, L., Halldin, J., Nilsson, L. H., Stolt, G., & Willander, A. (2003). A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. *Alcoholism, Clinical and Experimental Research*, 27(7), 1142–1149.
<https://doi.org/10.1097/01.ALC.0000075548.83053.A9>
- Beetham T, Saloner B, Gaye M, Wakeman SE, Frank RG, Barnett ML. Therapies offered at residential addiction treatment programs in the United States. *JAMA*. 2020;324(8):804-806.
- *Buprenorphine self-start*. (2020, November 5). Bridge to Treatment.
<https://bridgetotreatment.org/resource/rapid-guidance-for-patients-starting-buprenorphine-outside-of-hospitals-or-clinics/>
- Greenwald MK. Effects of buprenorphine maintenance dose on μ -opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. " *Neuropsychopharmacology*. 2003;28. 11:2000–2009.
- Goldsworthy RC, Schwartz NC, Mayhorn CB. Beyond abuse and exposure: framing the impact of prescription-medication sharing. *Am J Public Health*. 2008;98(6):1115-1121.
- Guardia, J., Caso, C., Arias, F., Gual, A., Sanahuja, J., Ramírez, M., Mengual, I., Gonzalvo, B., Segura, L., Trujols, J., & Casas, M. (2002). A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. *Alcoholism, Clinical and Experimental Research*, 26(9), 1381–1387.
<https://doi.org/10.1097/01.ALC.0000030561.15921.A9>
- Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. *N Engl J Med*. 2010;363(24):2320-2331.
- Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin

dependence in Sweden: a randomised, placebo-controlled trial. *Lancet*. 2003;361(9358):662-668.

- Krawczyk N, Mojtabai R, Stuart EA, et al. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services: Opioid agonist treatment and overdose. *Addiction*. 2020;115(9):1683-1694.
- Lähtenvuo, M., Tiihonen, J., Solismaa, A., Tanskanen, A., Mittendorfer-Rutz, E., & Taipale, H. (2024). Repurposing semaglutide and liraglutide for alcohol use disorder. *JAMA Psychiatry (Chicago, Ill.)*.
<https://doi.org/10.1001/jamapsychiatry.2024.3599>
- McPheeters, M., O'Connor, E. A., Riley, S., Kennedy, S. M., Voisin, C., Kuznacic, K., Coffey, C. P., Edlund, M. D., Bobashev, G., & Jonas, D. E. (2023). Pharmacotherapy for alcohol use disorder: A systematic review and meta-analysis: A systematic review and meta-analysis. *JAMA: The Journal of the American Medical Association*, 330(17), 1653–1665.
<https://doi.org/10.1001/jama.2023.19761>
- Orman JS and Keating GM. 2009. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. *Drugs* 69:577–607.
- Pettinati, H. M., Volpicelli, J. R., Pierce, J. D., Jr, & O'Brien, C. P. (2000). Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients: An intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. *Journal of Addictive Diseases*, 19(1), 71–83.
https://doi.org/10.1300/J069v19n01_06
- *Safe storage and disposal*. (n.d.). Michigan-open.org. Retrieved March 5, 2025, from <https://michigan-open.org/initiatives/safe-storage-and-disposal/>
- *Safe storage and disposal*. (n.d.). Michigan-open.org. Retrieved March 5, 2025, from <https://michigan-open.org/initiatives/safe-storage-and-disposal/>
- Saxon AJ, Oreskovich MR, Brkanac Z. Genetic determinants of addiction to opioids and cocaine. *Harv Rev Psychiatry*. 2005;13(4):218-232.
- Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. *JAMA Netw Open*. 2020;3(2):e1920622.
- Webster LR, Hansen E, Cater J, Smith T. A phase I placebo-controlled trial comparing the effects of buprenorphine buccal film and oral oxycodone

hydrochloride administration on respiratory drive. *Adv Ther.* 2020;37(11):4685-4696.

- Xie, Y., Choi, T., & Al-Aly, Z. (2025b). Mapping the effectiveness and risks of GLP-1 receptor agonists. *Nature Medicine*. <https://doi.org/10.1038/s41591-024-03412-w>
- Zweben JE, Sorensen JL, Shingle M, Blazes CK. Discontinuing methadone and buprenorphine: A review and clinical challenges. *J Addict Med.* 2020;Publish Ahead of Print. doi:10.1097/ADM.0000000000000789
-
-

